Logo
x

Search category

Subscribe Now

Approval

Insights+: The US FDA New Drug Approvals in October 2022

Insights+: The US FDA New Drug Approvals in October 2022

  • November 17, 2022
Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Cancer

Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Ca...

  • February 2, 2022
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

  • November 19, 2021
Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

  • November 19, 2021
OncoOne Entered into an Agreement with GenScript ProBio for the Manufacturing of Monoclonal Antibody Therapies Targeting oxMIF

OncoOne Entered into an Agreement with GenScript ProBio for the Manufacturing of Monoclonal Antibody Therapies Targeting oxMIF

  • November 18, 2021
GSK's Nucala (mepolizumab) Receives the EC's Approval for the Treatment of Eosinophil-Driven Diseases

GSK's Nucala (mepolizumab) Receives the EC's Approval for the Treatment of Eosinophil-Driven Diseases

  • November 18, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.